RVPH

0.9538

5.56% -0.0562

Dopo l'orario di chiusura: .92 -0.0338 -3.54%

Reviva Pharmaceuticals Holdings Inc (RVPH)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione

Precedente Chiudi:

$1.01

Aprire:

$0.99

Volume 24 ore:

803.26K

Relative Volume:

0.50

Capitalizzazione di mercato:

$49.84M

Reddito:

Utile/perdita netta:

$-37.65M

Rapporto P/E:

-0.5711

EPS:

-1.67

Flusso di cassa netto:

$-24.14M

1 W Prestazione:

-10.86%

1M Prestazione:

-33.76%

6M Prestazione:

-33.76%

1 anno Prestazione:

-74.77%

Intervallo 1D:

$0.9077

$1.0166

Intervallo di 1 settimana:

$0.9077

$1.17

Portata 52W:

$0.60

$4.28

Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Company Profile

Nome

Reviva Pharmaceuticals Holdings Inc

Settore

Healthcare (1164)

Industria

Biotechnology (681)

Telefono

(408) 501-8881

Indirizzo

10080 N WOLFE ROAD, CUPERTINO

Dipendente

Cinguettio

Prossima data di guadagno

2025-03-31

Ultimi documenti SEC

RVPH's Discussions on Twitter

Confronta RVPH con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
RVPH Reviva Pharmaceuticals Holdings Inc	0.9538	49.84M	0	-37.65M	-24.14M	-1.67
VRTX Vertex Pharmaceuticals Inc	484.82	131.41B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	634.23	72.26B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	591.87	36.10B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	270.02	35.03B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	272.17	28.24B	3.81B	-644.79M	-669.77M	-6.24

Reviva Pharmaceuticals Holdings Inc Stock (RVPH) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2023-09-20	Iniziato	ROTH MKM	Buy
2023-06-08	Iniziato	The Benchmark Company	Speculative Buy
2022-01-24	Iniziato	H.C. Wainwright	Buy

Reviva Pharmaceuticals Holdings Inc Borsa (RVPH) Ultime notizie

06:26 AM

Reviva Pharmaceuticals Delays Annual Report Filing - TipRanks

06:26 AM

04:06 AM

Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights - GlobeNewswire

04:06 AM

04:05 AM

Breakthrough: Reviva's Schizophrenia Treatment Delivers Powerful 1-Year Results, Losses Narrow - Stock Titan

04:05 AM

Mar 30, 2025

Reviva to Present Brilaroxazine Topline Data for Long-Term - GlobeNewswire

Mar 30, 2025

Major Clinical Data: 52-Week Results for New Schizophrenia Drug Coming at SIRS 2025 - Stock Titan

Mar 30, 2025

Mar 27, 2025

Reviva Pharmaceuticals (NASDAQ:RVPH) Stock Price Down 3.5% – What’s Next? - Defense World

Mar 27, 2025

Mar 02, 2025

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives Average Rating of “Buy” from Brokerages - Defense World

Mar 02, 2025

Feb 18, 2025

Reviva Pharmaceuticals adjusts executive pay, grants stock options By Investing.com - Investing.com South Africa

Feb 18, 2025

Reviva Pharmaceuticals adjusts executive pay, grants stock options - Investing.com India

Feb 18, 2025

Reviva Pharmaceuticals Approves Executive Compensation Changes - TipRanks

Feb 18, 2025

Feb 12, 2025

Unusually active option classes on open February 12th - TipRanks

Feb 12, 2025

Feb 10, 2025

Get in on Reviva Pharmaceuticals Holdings Inc’s (RVPH) buy-in window today! - SETE News

Feb 10, 2025

Feb 08, 2025

Analysts Set Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) PT at $11.40 - MarketBeat

Feb 08, 2025

Feb 06, 2025

Adversity is less terrifying than hope: Reviva Pharmaceuticals Holdings Inc (RVPH) - SETE News

Feb 06, 2025

Feb 05, 2025

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives Average Recommendation of “Buy” from Analysts - Defense World

Feb 05, 2025

How should investors view Reviva Pharmaceuticals Holdings Inc (RVPH)? - US Post News

Feb 05, 2025

Feb 04, 2025